+181.9%
GILD vs MRNA
+554.4%
-372.5%
-30.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | +5.4% | -6.1% | -1.1% |
| 7D | -4.8% | -1.1% | -3.7% | -4.8% |
| 30D | +5.8% | +126.1% | -120.3% | -3.2% |
| 3M | +14.9% | +190.0% | -175.1% | +2.6% |
| 6M | -0.4% | +157.2% | -157.6% | -10.4% |
| YTD | +18.5% | +388.2% | -369.7% | +0.4% |
| 1Y | +25.1% | +467.0% | -441.9% | +4.1% |
| 3Y | +105.9% | +36.1% | +69.8% | +86.6% |
| 5Y | +143.0% | -68.0% | +210.9% | +140.3% |
| All | +181.9% | +554.4% | -372.5% | +89.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling